SHAMARUKH KABIR: Open Payments
NPI 1851826077 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,400 in 95 payments from 16 companies in 2025. Trend: 2023 $1,723 · 2024 $1,734 · 2025 $2,400
Food & beverage: $2,400
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $566 |
| Otsuka America Pharmaceutical, Inc. | 17 | $418 |
| E.R. Squibb & Sons, L.L.C. | 7 | $270 |
| ABBVIE INC. | 14 | $266 |
| Axsome Therapeutics, Inc. | 8 | $200 |
| Supernus Pharmaceuticals, Inc. | 3 | $156 |
| Neurocrine BioSciences, Inc. | 6 | $148 |
| Janssen Pharmaceuticals, Inc | 4 | $112 |
| Teva Pharmaceuticals USA, Inc. | 4 | $97 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
Products named: CAPLYTA, REXULTI, COBENFY, VRAYLAR, Auvelity, Qelbree, INGREZZA, ABILIFY MAINTENA.
Industry payments across TX — which companies pay providers there.
